Apljack, I think your making a smart investment as a short or long term trade. Dr. Crooke had trouble stopping himself from giving details about other partnership discussions during the GSK presentation. The next agreements are going to be larger where pharma locks-in all targets in a certain area. I wouldn't be surprised if their already in negotiations for discovery-stage anti-thrombolitic targets. ISIS is about to bring "FXI" into Phase I & they stated they've already selected a second target for clotting disorders.
Pharma is being forced into the RNA space due to generic threats. Its virtually impossible for generics to copy these drugs & ISIS is years ahead of any of the RNA plays so pharma has to come to them.
The more info we get on MIPO's safety profile the better it looks.
News 
Market Data 
Discover 
AI
